Unknown PHASE2 INTERVENTIONAL 1-arm NCT04337593

Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL

Combination of Basiliximab and Pegaspargase in the Treatment of Relapsed/Refractory Extranodal NK/T-cell Lymphoma, Nasal Type: a Single Arm, Open Label, Phase 2 Trial

Sponsor: Beijing Tongren Hospital

Conditions Extranodal NK/T-cell Lymphoma

Interventions Basiliximab Pegaspargase

Updated 5 times since 2020 Last updated: Apr 6, 2020 Started: Jun 1, 2020 Primary completion: May 31, 2022 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Extranodal NK/T-cell Lymphoma, this trial is ongoing. The trial is conducted by Beijing Tongren Hospital and has accumulated 5 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Feb 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Feb 2023 [monthly]

Not Yet Recruiting PHASE2
May 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Tongren Hospital

Data source: Beijing Tongren Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.